Clinical trials: Transient-ischaemic Attack
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation
The purpose of this study are 1) to characterize the primary and secondary prevention patients, 2) to calculate incidence rates of stroke/SE or major bleeding in each cohort and 3) to investigate for Japanese secondary prevention…
- Trial name
- NCT05321810
- Testing
- Apixaban, Warfarin
- Where
- Japan
- Volunteers
- 193,565 people
- Sponsor
- Pfizer
Ischemic Stroke, Transient Ischemic Attack
VISSIT Intracranial Stent Study for Ischemic Therapy
The main objective of this study is to prospectively evaluate the safety, probable benefit, and effectiveness of the PHAROS Vitesse Neurovascular Stent System in a multicenter, randomized clinical trial.
- Trial name
- VISSIT (NCT00816166)
- Testing
- Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel), Aspirin and Clopidogrel (Medical therapy)
- Volunteers
- 125 people
- Sponsor
- Codman & Shurtleff
Thrombosis
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are…
- Trial name
- NCT02671461
- Testing
- BMS-986141, Aspirin
- Where
- 33 sites in United States, Japan
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Patent Foramen Ovale
PFx Closure System in Subjects With Cryptogenic Stroke,Transient Ischemic Attack,Migraine or Decompression Illness(PFO)
The primary objective of this study is to demonstrate the safety and performance of the PFx Closure System when utilized for patients with PFOs suffering from cryptogenic stroke, transient ischemic attack, migraine or…
- Trial name
- NCT00335296
- Testing
- PFx catheter
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 100 people
- Sponsor
- Cierra
Peripheral Vascular Diseases
Screening DIVA - Diffuse Vascular Disease
Primary Objective: To investigate the value of the Edinburgh Claudication Questionnaire (ECQ) against the ankle-brachial index (ABI) in Canadian patients mainly followed in general practice, with documented acute coronary…
- Trial name
- NCT01076738
- Where
- Canada
- Volunteers
- 2,233 people
- Sponsor
- Sanofi
Acute Ischemic Stroke, Transient Ischemic Attack (TIA)
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
- Trial name
- AXIOMATIC-SSP (NCT03766581)
- Testing
- BMS-986177, Clopidogrel, Aspirin
- Where
- 424 sites in United States, Argentina and 27 more
- Volunteers
- 2,366 people
- Sponsor
- Bristol-Myers Squibb
Ischaemic Attack, Transient
Safety Escalating Repeat IV, in Stroke Patients
The purpose of this study is to is to test increasing repeat doses of GSK249320 compared to placebo in patients with stroke.
- Trial name
- MAG111539 (NCT00833989)
- Testing
- GSK249320
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders, Heart Disease
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease.
- Conditions
- Migraine Disorders, Heart Disease, Cerebrovascular Accident, TIA (Transient Ischemic Attack)
- Trial name
- NCT00662818
- Testing
- Telcagepant, Acetaminophen/Paracetamol
- Volunteers
- 165 people
- Sponsor
- Merck Sharp & Dohme LLC
Patent Foramen Ovale, Stroke
Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)
The primary objective of the study is to determine whether the STARFlex® septal closure system will safely and effectively prevent a recurrent embolic stroke/transient ischemic attack (TIA) and mortality in patients with a PFO…
- Conditions
- Patent Foramen Ovale, Stroke, Ischemic Attack, Transient
- Trial name
- NCT00201461
- Testing
- STARFlex septal closure system, Best medical therapy
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- NMT Medical
Ischemic Stroke, Atrial Fibrillation
Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)
The proposed study will validate the clinical use of new biomarker blood tests to identify blood components that may differentiate between diverse stroke etiologies and clinical outcomes as listed below: 1.
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Transient Ischemic Attacks, Transient Cerebrovascular Events
- Trial name
- BASE (NCT02014896)
- Testing
- Biomarker blood draw
- Where
- 22 sites in United States
- Volunteers
- 1,750 people
- Sponsor
- Ischemia Care LLC
PFO, Stroke
PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression Illness
The primary object of this study is to demonstrate the continued safety and performance of the PFx Closure System when utilized for patients with PFOs suffering from cryptogenic stroke, transient ischemic attack, migraine or…
- Conditions
- PFO, Stroke, Transient Ischemic Attack, Migraine
- Trial name
- Paradigm IV (NCT00529945)
- Testing
- PFx Closure System
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Cierra
Acute Ischaemic Stroke, Transient Ischaemic Attack
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
- Trial name
- THALES (NCT03354429)
- Testing
- Ticagrelor
- Where
- 387 sites in Argentina, Australia and 26 more
- Volunteers
- 11,016 people
- Sponsor
- AstraZeneca
Acute Stroke, Transient Ischemic Attack
The Recurrence Study
The primarily goal of the research is to better understand progression of disease in patients who present with an acute stroke to the Hamad General Hospital (HGH) stroke and Transient Ischemic Attack (TIA) clinic.
- Trial name
- NCT03244215
- Testing
- Corneal Confocal Imaging, Magnetic resonance Imaging, Blood sample
- Where
- Qatar
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Carotid Stenosis
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GEMSAV (NCT01344447)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 56 sites in United States, Argentina and 12 more
- Volunteers
- 479 people
- Sponsor
- Bayer
Stroke, Embolism
Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients
This is local prospective multicenter observational non-interventional local study. Primary study objective is investigate and describe prescription pattern of neurologists in secondary stroke or non-CNS (non-Central Nervous…
- Trial name
- NEURO-XAR (NCT01925755)
- Testing
- Rivaroxaban ( Xarelto, BAY59-7939)
- Where
- Russia
- Volunteers
- 209 people
- Sponsor
- Bayer
Carotid Artery Disease, Stroke
Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy
The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA)…
- Conditions
- Carotid Artery Disease, Stroke, Amaurosis Fugax, Transient Ischemic Attack (TIA)
- Trial name
- CANOPY (NCT01445613)
- Testing
- RX Acculink Carotid Stent System (RX Acculink)
- Where
- United States
- Volunteers
- 1,203 people
- Sponsor
- Abbott Medical Devices
Carotid Stenosis, Atherosclerosis
Revacept in Symptomatic Carotid Stenosis
Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone.
- Conditions
- Carotid Stenosis, Atherosclerosis, Stroke, Transient-ischaemic Attack
- Trial name
- RevaceptCS02 (NCT01645306)
- Testing
- Revacept
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 158 people
- Sponsor
- AdvanceCor GmbH
Ischemic Stroke; Ischemic Attack, Transient
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
- Trial name
- LIBREXIA-STROK (NCT05702034)
- Testing
- Milvexian
- Where
- 880 sites in United States, Argentina and 45 more
- Volunteers
- 12,523 people
- Sponsor
- Janssen Research & Development, LLC
Infarction, Anterior Cerebral Artery, Infarction, Middle Cerebral Artery
An Observational Registry Study of LUOTAI in Patients With Acute Ischemic Stroke in Vietnam
Ischemic stroke occurs when an artery to the brain is blocked. If the artery remains blocked for more than a few minutes, the brain cells may die. This is why immediate medical treatment is critical.
- Conditions
- Infarction, Anterior Cerebral Artery, Infarction, Middle Cerebral Artery, Ischemic Attack, Transient
- Trial name
- NCT03679364
- Where
- 3 sites in Vietnam
- Volunteers
- 364 people
- Sponsor
- KPC Pharmaceuticals, Inc
Atrial Fibrillation
A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation
The purpose of this study is to investigate the optimal daily dose and dose regimen of YM150 in subjects with non-valvular atrial fibrillation (NVAF), primarily based on safety and tolerability data.
- Trial name
- OPAL-2 (NCT00938730)
- Testing
- YM150, Warfarin
- Where
- 170 sites in Australia, Austria and 21 more
- Volunteers
- 1,280 people
- Sponsor
- Astellas Pharma Inc